Table 6.
Overview of studies using intra-arterial chemotherapy for HCC in Asia.
| Investigator | Number of patients | Drug(s) | Efficacy | Major (grade 3 or 4) toxicity | Reference |
|---|---|---|---|---|---|
| Baek et al. | 34 | FUDR | RR: 41.2%; DCR 61.8% | Leucopenia (2.9%); thrombocytopenia (2.9%); gastric ulcer (11.8%); mucositis (8.8%) | [11] |
| Okusaka et al. | 79 (TACE); 82 (IACT) | Zinostatin stimalamer | RR: 48.1% (TACE); RR: 34.2% (IACT) | Thrombocytopenia (3.7% in IACT group); AST (28%); ALT (20%) | [12] |
| Kim et al. | 36 | 5-FU and cisplatin | RR: 16.7% | Thrombocytopenia (6.4%); hepatitis with ALT >2.5 times UNL (38.7%) | [13] |
| Mazzanti et al. | 24 | Folinic acid and 5-FU | RR: 54.2% | No | [14] |
| Chung et al. | 23 | IA cisplatin and SC INF-α | RR: 33% | NA | [15] |
| Park et al. | 41 | 5-FU and cisplatin | RR: 22%; SD: 34.1% | Leukopenia (2.4%); thrombocytopenia (4.8%); bilirubin (12.2%) | [16] |
| Obi et al. | 116 | IA 5-FU and SC INF-α | RR: 51% | NA | [17] |
| Ando et al. | 48 | Cisplatin and 5-FU | RR: 43% | Hepatic dysfunction (8.3%) | [18] |
| Ota et al. | 55 | IA 5-FU and SC INF-α | RR: 43.6% | Leucopenia (5.5%); thrombocytopenia (9.1%) | [19] |
| Woo et al. | 32 (low dose); 36 (high dose) | Cisplatin and 5-FU | Low dose RR: 0% High dose RR: 16.7% |
Neutropenia (3.1% in low dose, 2.8% in high dose); hyperbilirubinemia (3.1% in low dose, 2.8% in high dose) | [20] |
| Tanioka et al. | 38 | Cisplatin and 5-FU | PR: 47% | NA | [21] |
| Rau et al. | 50 | Cisplatin and doxorubicin | RR: 22% (intent-to-treat) RR: 36.7% (>2 cycles) DCR: 70% |
Neutropenia (8%) | This study |